NL-201 in Patients With Relapsed or Refractory Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Patients will have tests and exams to see if they are eligible for the clinical trial. If eligible, the patient will receive NL-201 treatment by vein. Tumor response to treatment will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease progression. Patients will be ab...
Patients will have tests and exams to see if they are eligible for the clinical trial. If eligible, the patient will receive NL-201 treatment by vein. Tumor response to treatment will be assessed every 6 weeks for 12 weeks, and every 12 weeks thereafter until disease progression. Patients will be able to receive study treatment as long as it is tolerated and there is evidence of clinical benefit. Safety follow- up will occur within 7 days after the last dose of NL-201. Patients will then enter long-term follow-up until starting a subsequent therapy.
Tracking Information
- NCT #
- NCT04659629
- Collaborators
- Not Provided
- Investigators
- Study Director: Umut Ulge, MD, PhD Neoleukin
Get Well Soon